Policymakers across the world are regularly required to make crucial decisions about resource allocation and prioritize interventions – medicine A or medicine B, subsidize heart surgery or expand the immunization program. This process is required to be transparent, accountable a

Benjarin Santatiwongchai is Head of Communication for HITAP. Having studied BSc in Pharmacy from Mahidol University, her knowledge in current and emerging medical technologies and interventions has led her to become involved with Health Technology Assessment. In 2012, she completed her MSc in Health Economics at the University of York. She is now a

Beijing Children’s Hospital, Capital Medical University, National Centre for Children’s Health of China are committed to advancing skills in conducting comprehensive clinical evaluations of medicines. This commitment is evident through a variety of initiatives, including workshops, training, and aca

t is an uncomfortable question that, in today’s world, is often asked by expectant mothers who had more than one male partner at the time they became pregnant. Who is the father?With more than half of births to women under 30 now out of wedlock, it is a question that may arise more often.Now blood t

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. Inthira Yamabhai; Richard D. Smith Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T

Abstract Introduction Despite the documented benefits of using health technology assessments (HTA) to inform resource allocation in health care systems, HTA remains underused, especially in low- and middle-income countries. A survey of global health practitioners was conducted to reveal the top

On 21st September 2020, HITAP joined representatives of the Ministry of Public Health (MOPH) Thailand and the National Health Security Office (NHSO) at the Kenyan Universal Health Coverage (UHC) Fund Taskforce meeting chaired by Mr. Geoffrey Malombe from National Treasury and Dr. Mercy Mwangangi, Ch

(Reuters) – AstraZeneca is to conduct a new global clinical trial of key new heart drug Brilinta involving 11,500 patients with peripheral artery disease, Britain’s second biggest drugmaker said on Tuesday.Peripheral artery disease affects around 27 million people in Europe and North America, with s